Transglutaminase 2 protects against ischemic stroke.

Transglutaminase 2 (TG2) is a multifunctional protein that modulates cell survival and death pathways. It is upregulated in numerous ischemic models, and protects primary neurons from oxygen and glucose deprivation. TG2 binds to the hypoxia inducible factor (HIF) 1beta and decreases the upregulation of hypoxic-induced proapoptotic genes. To investigate the role of TG2 in ischemic stroke in vivo, we used the murine, permanent middle cerebral artery (MCA) ligation model. TG2 mRNA levels are increased after MCA ligations, and transgenic mice that express human TG2 in neurons had significantly smaller infarct volumes than wild type littermates. Further, TG2 translocates into the nucleus within 2h post ligation. Nuclear-localized TG2 is also apparent in human stroke cases. TG2 suppressed the upregulation of the HIF-induced, proapoptotic gene, Noxa. The findings of this study indicate that TG2 plays a role in attenuating ischemic-induced cell death possibly by modulating hypoxic-induced transcriptional processes.

Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.

The cause of Huntington's disease (HD) is a pathological expansion of the polyglutamine domain within the NH(2)-terminal region of huntingtin. Neuronal intranuclear inclusions and cytoplasmic aggregates composed of the mutant huntingtin within certain neuronal populations are a characteristic hallmark of HD. Because in vitro expanded polyglutamine repeats are glutaminyl-donor substrates of tissue transglutaminase (tTG), it has been hypothesized that tTG may contribute to the formation of these aggregates in HD. Therefore, it is of fundamental importance to establish whether tTG plays a significant role in the formation of mutant huntingtin aggregates in the cell. Human neuroblastoma SH-SY5Y cells were stably transfected with truncated NH(2)-terminal huntingtin constructs containing 18 (wild type) or 82 (mutant) glutamines. In the cells expressing the mutant truncated huntingtin construct, numerous SDS-resistant aggregates were present in the cytoplasm and nucleus. Even though numerous aggregates were present in the mutant huntingtin-expressing cells, tTG did not coprecipitate with mutant truncated huntingtin. Further, tTG was totally excluded from the aggregates, and significantly increasing tTG expression had no effect on the number of aggregates or their intracellular localization (cytoplasm or nucleus). When a YFP-tagged mutant truncated huntingtin construct was transiently transfected into cells that express no detectable tTG due to stable transfection with a tTG antisense construct, there was extensive aggregate formation. These findings clearly demonstrate that tTG is not required for aggregate formation, and does not facilitate the process of aggregate formation. Therefore, in HD, as well as in other polyglutamine diseases, tTG is unlikely to play a role in the formation of aggregates.

Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee -- a prospective randomized clinical trial.

In this independent prospective randomized trial, we compared the clinical effectiveness, functional outcome and patient satisfaction following intra articular injection with two viscosupplementation agents - Hylan G-F-20 (n=199) and Sodium Hyaluronate (n=193) in patients with osteoarthritis (OA) of the knee. All patients were prospectively reviewed by blinded independent assessors at pre injection, 6 weeks, 3, 6, 12 months. Knee pain and patient satisfaction were measured on a visual analogue scale. Functional outcome was assessed using WOMAC, Oxford knee score and EuroQol EQ-5D scores. Knee pain on VAS improved from 6.7 to 3.2 by 6 weeks (p=0.02) and was sustained until 12 months (3.7, p=0.04) with Hylan G-F 20. In the Sodium Hyaluronate group, pain improved from 6.6 to 5.7 at 6 weeks (p>0.05) and to 4.1 at 3 months (p=0.04) but was sustained only until 6 months (5.9, p>0.05). Improvement in the WOMAC pain subscale was significantly superior in the Hylan G-F 20 group at 3 months (p=0.02), 6 months (p=0.01) and 12 months (p=0.007). There was no significant difference in the EQ-5D scores at 6 weeks and 3 months between the two groups. The numbers of treatment related adverse events were higher (39 vs. 30) in the Hylan G-F 20 group. One patient in the Hylan G-F 20 group who had a serious adverse event was also included in the final analysis. Although both treatments offered significant pain reduction, it was achieved earlier and sustained for a longer period with Hylan G-F 20. From this study, it appeared that the clinical effectiveness and general patient satisfaction are better amongst patients who received Hylan G-F 20.

Inhibition of iron deficiency stress response in cucumber by rare earth elements.

We investigated the influence of the trivalent scandium (Sc), chromium (Cr), gallium (Ga), yttrium (Y) and lanthanum (La) on both the function and activity of ferric chelate reductase (FCR) in cucumber (Cucumis sativus L.) roots. Cucumber seedlings were grown for 1week in a nutrient solution without Fe or in some experiments with 10microM FeEDTA. Intact root systems were assayed for FCR activity in a medium at pH 5.0 containing 100microM FeEDTA with the ferrous chelating agent Ferrozine. Addition of 100microM concentrations of the EDTA complexes of Sc, Cr, Ga, Y and La did not inhibit FCR in Fe-deficient roots. When Fe-deficient roots were grown with 10microM LaCl(3), ScCl(3), or YCl(3) for 3days, FCR activity decreased to 23%, 15% and 1%, respectively, of the activity of Fe-deficient plants grown without trivalent metal addition. Additionally, these trivalent metals suppressed proton secretion. Growth of Fe-deficient plants with 80microM Ga(2)(SO(4))(3) decreased FCR activity to 35% of the control activity while 80microM CrEDTA did not affect FCR activity. With the addition of either FeEDTA or YCl(3), FCR activity decreased to less than 5% of the activity of the Fe-deficient control roots in 3days. Addition of FeEDTA, but not Y, resulted in recovery from Fe deficiency as indicated by increasing chlorophyll content of leaves.

Tissue transglutaminase: a possible role in neurodegenerative diseases.

Tissue transglutaminase is a multifunctional protein that is likely to play a role in numerous processes in the nervous system. Tissue transglutaminase posttranslationally modifies proteins by transamidation of specific polypeptide bound glutamines. This action results in the formation of protein crosslinks or the incorporation of polyamines into substrate proteins, modifications that likely have significant effects on neural function. Tissue transglutaminase is a unique member of the transglutaminase family as in addition to catalyzing the calcium-dependent transamidation reaction, it also binds and hydrolyzes ATP and Guanosine 5'-triphosphate and may play a role in signal transduction. Tissue transglutaminase is a highly regulated and inducible enzyme that is developmentally regulated in the nervous system. In vitro, numerous substrates of tissue transglutaminase have been identified, and several of these proteins have been shown to be in situ substrates as well. Several specific roles for tissue transglutaminase have been described and there is evidence that tissue transglutaminase may also play a role in apoptosis. Recent findings have provided evidence that dysregulation of tissue transglutaminase may contribute to the pathology of several neurodegenerative conditions including Alzheimer's disease and Huntington's disease. In both of these diseases tissue transglutaminase and transglutaminase activity are elevated compared to age-matched controls. Further, immunohistochemical studies have demonstrated that there is an increase in tissue transglutaminase reactivity in affected neurons in both Alzheimer's and Huntington's disease. Although intriguing, many issues remain to be addressed to definitively establish a role for tissue transglutaminase in these neurodegenerative diseases.

Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis.

Although tissue transglutaminase (tTG) has been recognized as a mediator of apoptosis in various experimental models, little is currently known about the molecular mechanisms by which this protein modulates cell death. Recent work from our laboratory has shown that activation of tTG in cells exposed to the apoptotic inducer calphostin C triggers the crosslinking of dual leucine zipper-bearing kinase (DLK), a proapoptotic kinase acting as an essential component of the c-Jun amino-terminal kinase (JNK) signaling pathway. As a consequence of this observation, we have undertaken experiments to investigate the functional relevance of DLK oligomerization in tTG-mediated apoptosis. Our results indicate that, in cells undergoing calphostin C-induced apoptosis, tTG-dependent DLK oligomerization occurs early in the apoptotic response. Both immunocomplex kinase assays and immunoblotting with phosphospecific antibodies revealed that oligomer formation by tTG-mediated crosslinking reactions significantly enhanced the kinase activity of DLK and its ability to activate the JNK pathway. Moreover, functional studies demonstrate that tTG-mediated oligomerization of wild-type DLK sensitizes cells to calphostin C-induced apoptosis, while crosslinking of a kinase-inactive variant of DLK does not. Collectively, these data strongly suggest that tTG facilitates apoptosis, at least partly, by oligomerization and activation of the proapoptotic kinase DLK.

Oral aluminum alters in vitro protein phosphorylation and kinase activities in rat brain.

Chronic, oral administration of aluminum to rats increases the in vivo concentration of cyclic AMP and the phosphorylation of microtubule-associated protein-2 (MAP-2) and the 200 kD neurofilament subunit (15,16). In the present study, the effect of this treatment on endogenous protein phosphorylation in soluble and particulate fractions prepared from cerebral cortices was examined. Chronic aluminum treatment significantly elevated the basal and cyclic AMP-dependent phosphorylation of 11-12 endogenous proteins in the soluble fraction prepared from cerebral cortices. Endogenous protein phosphorylation in the soluble fraction occurring in the presence of Ca++ alone or Ca++, phorbol 12-myristate 13-acetate and phosphatidylserine was not significantly altered by aluminum treatment. In the particulate fraction the phosphorylation of several proteins was significantly decreased by aluminum administration; however, the phosphorylation of the majority of protein substrates remained unaltered. Aluminum treatment did not alter the activities of cyclic AMP-dependent protein kinase or protein tyrosine kinase in the soluble and particulate fractions. The activity of Ca++/phospholipid-dependent protein kinase (protein kinase C) was increased in the particulate fraction of aluminum-fed rats. These results clearly demonstrate that specific effects on protein phosphorylation and protein kinase activities result from in vivo aluminum administration.

Metal-catalyzed oxidation of bovine neurofilaments in vitro.

Neurofilaments (NF) are important determinants of the shape and size of nerve cells. The oxidation of NF, relevant to aging, neurodegenerative disorders, and axonal (Wallerian) degeneration, has not been studied. In this investigation, we have combined biochemical and ultrastructural methods to study the metal-catalyzed oxidation (MCO) of bovine NF using an ascorbate/Fe+3/O2 system. The oxidation of NF proteins was documented by increases in carbonyl content, which were time- and concentration-dependent. Polyacrylamide gel electrophoresis (PAGE) and immunoblot analyses revealed the fragmentation of oxidized NF proteins, predominantly NF-H and NF-M. Electron microscopy (EM) showed that oxidized NF formed dense aggregates and bundles of laterally aggregated filaments. Finally, we also demonstrated that oxidized NF proteins were more susceptible to calpain proteolysis. In view of the growing evidence supporting increased oxidative stress on the nervous system in aging and the report of Cu/Zn superoxide dismutase mutation in familial motor neuron disease, oxidative injury of NF may be relevant to cell atrophy and degeneration of nerve cells and to the formation of abnormal cytoskeletal structures.

Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons.

The modulation of tau phosphorylation and localization in response to insulin-like growth factor-1 or insulin was examined in primary cultures of rat cortical neurons. Insulin and insulin-like growth factor-1 treatment resulted in a rapid and transient increase in tau phosphorylation at specific epitopes. These effects were completely inhibited by lithium, revealing that the insulin and insulin-like growth factor-1 induced changes in tau phosphorylation were mediated by glycogen synthase kinase-3beta. In addition, the increase in tau phosphorylation directly correlated with a transient dissociation of tau from the cytoskeleton, indicating that insulin and insulin-like growth factor-1 treatment resulted in a change in tau localization. Using immunocytochemistry, it was also demonstrated that treatment of neurons with insulin-like growth factor-1 for 3 min resulted in a redistribution of tau to the growth cone and the distal segment of the axons. Further, insulin-like growth factor-1 treatment resulted in an increased immunoreactivity with the phospho-dependent antibody AT8 in the same areas of the axons. Thus, the phosphorylation state and distribution of tau can be modulated by insulin and insulin-like growth factor-1 signaling pathways involving glycogen synthase kinase-3beta. We propose that by transiently increasing tau phosphorylation, insulin and insulin-like growth factor-1 may contribute to the reorganization of the cytoskeleton necessary for the development and growth of the neurites.

Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells.

Tissue transglutaminase is a normal constituent of the central and peripheral nervous systems and in rats transglutaminase activity in brain and spinal cord is highest during fetal stages when axonal outgrowth is occurring. Further, treatment of human neuroblastoma SH-SY5Y cells with retinoic acid results in the cells withdrawing from the cell cycle and extending neurites, in the same time frame that tissue transglutaminase expression significantly increases. Considering these and other previous findings, this study was carried out to determine whether tissue transglutaminase is involved in neuronal differentiation of SH-SY5Y cells. For these studies SH-SY5Y cells stably overexpressing wild-type tissue transglutaminase, an inactive tissue transglutaminase mutant (C277S) or an antisense tissue transglutaminase construct (which decreased endogenous tissue transglutaminase below detectable levels) were used. SH-SY5Y cells overexpressing wild-type tissue transglutaminase spontaneously differentiated into a neuronal phenotype when grown in low-serum media. In contrast, cells overexpressing inactive tissue transglutaminase or the antisense tissue transglutaminase continued to proliferate and exhibit a flat polygenic morphology even when maintained in low-serum conditions. In addition, increased tissue transglutaminase expression in response to retinoic acid was abolished in the antisense tissue transglutaminase cells, and antisense and mutant tissue transglutaminase expressing cells did not extend neurites in response to retinoic acid. Moreover, wild-type and inactive tissue transglutaminase exhibited differential intracellular localization. These data indicate that tissue transglutaminase is necessary and sufficient for neuronal differentiation of human neuroblastoma SH-SY5Y cells.

Tau protein in normal and Alzheimer's disease brain.

In 1975, Weingarten and colleagues isolated a protein factor that was able to induce microtubule formation. They called this factor tau (t). Some ten years later a new era of research on this microtubule-associated protein was launched when several groups almost simultaneously discovered that tau was the predominant protein component of the paired helical filaments (PHFs) and neurofibrillary tangles (NFTs) which are characteristic pathological lesions of the Alzheimer's disease brain. Subsequent findings that PHF-tau isolated from Alzheimer's disease brain was phosphorylated to a greater extent than non-PHF tau, led to extensive investigation into the posttranslational modifications (mainly phosphorylation) of tau in normal and Alzheimer's disease brain. The present review highlights the literature concerning the normal functioning and processing of tau protein, and examines the evidence for the involvement of the abnormal posttranslational processing of tau in the pathology of Alzheimer's disease. Finally, speculation as to the relationship between abnormal processing of tau, other subcellular abnormalities seen in Alzheimer's disease, and the pathological causes of the disease are discussed.

Tau protein in normal and Alzheimer's disease brain: an update.

Tau is a microtubule-associated protein that, in a hyperphosphorylated form, comprises the main component of the paired helical filaments and neurofibrillary tangles found in Alzheimer's Disease (AD) brain. It is therefore important to understand the normal functioning and processing of tau protein, and the abnormal posttranslational processing of tau in AD pathology. In 1996, Johnson and Jenkins reviewed the literature on the biochemistry, function, and phosphorylation of tau in normal and AD brain. Since that time, numerous publications have come out further elucidating the properties of tau. The present review updates the topics originally covered in the 1996 review, as well as presents a number of new topics. For example, mutations in the tau gene have been found in several non-AD, autosomal dominant neurodegenerative disorders that exhibit extensive neurofibrillary pathology. In addition, there is increasing evidence that tau may be involved in signal transduction, organelle transport, and cell growth, independent of its microtubule-binding functions. Taken together, the research reviewed here demonstrates that tau is a very complex protein with various functions that are intricately regulated. It is clear that more research is required to completely understand the functions and regulation of tau in normal and AD brain.

Tau complexes with phospholipase C-gamma in situ.

Based on the results of recent in vitro studies, tau has been proposed to be involved in regulating signal transduction through the phospholipase C-gamma (PLC-gamma) signaling pathway. The present study provides support for the physiological relevance of this hypothesis by demonstrating the existence of a tau-PLC-gamma complex in situ in a human neuroblastoma cell line. Both PLC-gamma and PLC-delta, but not PLC-beta, co-purified with microtubule-associated proteins. PLC-gamma, but neither PLC-delta nor PLC-beta, co-immunoprecipitated with tau, and the PLC co-precipitating with tau was enzymatically active. Additionally, both tau and MAP-2 co-precipitated with PLC-gamma. These studies indicate that tau associates, either directly or indirectly, with PLC-gamma in situ, suggesting that tau may be appropriately localized to participate in the regulation of signal transduction through the PLC-gamma pathway in vivo.

Pavlovian conditioning alters cortical microtubule-associated protein-2.

Three experiments indicate that Pavlovian conditioning to tone alters microtubule-associated protein-2 (MAP-2) in the temporal cortex. First, increased MAP-2 immunohistochemistry was evident in temporal cortex following tone-shock pairings but not light-shock pairings. In the second experiment, animals given tone paired with shock (compared with animals trained with tone unpaired with shock or given tone only) showed MAP-2 immunohistochemical changes in the temporal cortex, as well as in the frontal and cingulate cortex, the hippocampus and amygdala. In experiment 3, quantitative immunoblots showed decreased intact MAP-2 and increased breakdown products selectively in temporal cortex following fear conditioning to tone. Conditioning to tone also increased sizes of MAP-2 rich pyramidal somata and apical dendrites in temporal and frontal cortex.

Metal (Fe3+) affinity chromatography: differential adsorption of tau phosphoproteins.

Tau is a neuronal cytoskeletal protein consisting of a group of isoforms with apparent molecular masses ranging from 45 to 62 kDa. Tau purified from brain exists in multiple phosphorylated forms and abnormally phosphorylated tau appears to play an important role in the neuropathology of Alzheimer's disease. To separate the differentially phosphorylated populations of tau, a chromatographic technique using ferric ions adsorbed onto iminodiacetic acid substituted Sepharose was developed. Several distinct populations of tau were isolated based on the phosphorylation state. These preparations can be used for further investigation of how each specific phosphorylation state modulates the metabolism and function of tau.

Phosphorylation of rat brain cytoskeletal proteins is increased after orally administered aluminum.

In rats, administration of 0.3% aluminum in the drinking water for 4-5 weeks significantly increased the in vivo incorporation of 32-phosphorous (32Pi) into proteins with apparent molecular weights of 300 and 210 kDa in the brainstem and cerebral cortex. The identities of these two phosphoproteins as microtubule-associated protein-2 (MAP-2) and the 200 kDa neurofilament subunit (NF), respectively, were established using immunoprecipitation techniques with monoclonal antibodies. Aluminum treatment did not significantly change the amount of MAP-2 or 200 kDa NF in the cerebral cortex and brainstem. Phosphorylation of MAP-2 in aluminum-treated rats in the brainstem and cerebral cortex was 163 and 155% of control values, respectively. The phosphorylation of 200 kDa NF in the brainstem and cerebral cortex of aluminum-treated rats was 148 and 209% of control values, respectively. These results demonstrate that chronic oral aluminum administration to rats increases the phosphorylation of certain cytoskeletal proteins. This treatment regimen may provide a model system with which the mechanisms and consequences of altered in vivo phosphorylation of cytoskeletal proteins can be studied.

Phosphorylation of microtubule-associated protein tau on Ser 262 by an embryonic 100 kDa protein kinase.

This study examined the phosphorylation of tau on Ser 262, within the first microtubule-binding domain, by a developmentally regulated 100 kDa protein kinase exhibiting significantly greater activity in the embryonic rat brain than in the adult rat brain. This protein kinase co-purified with microtubules and co-immunoprecipitated with both tau and MAP-2. In addition to phosphorylating tau, MAP-2, and a Ser 262-containing peptide, the present protein kinase activity was shown to autophosphorylate as determined by the in-gel kinase assay in the absence of any protein or peptide polymerized into the matrix. Phosphorylation of tau with this protein kinase significantly reduced the tau-microtubule interaction, and the effect was significantly greater with microtubule-associated protein (MAP) preparations from embryonic brain than with preparations from the adult. Ser 262 is phosphorylated extensively in paired helical filament (PHF) tau from Alzheimer's disease (AD) brain, to a lesser extent in fetal tau, and only to a very minor extent in biopsy-derived human tau. Because the 100 kDa protein kinase activity phosphorylates Ser 262 and is higher in the fetal brain than the adult brain, it is hypothesized that an inappropriate re-expression and/or re-activation of this or a similar developmentally regulated protein kinase could contribute to the phosphorylation of Ser 262 in PHF-tau, and thus play a role in the pathogenesis of AD.

Aluminum alters cyclic AMP and cyclic GMP levels but not presynaptic cholinergic markers in rat brain in vivo.

Oral administration of 0.3% aluminum (citrate or sulfate salt) for 4 weeks significantly elevated adenosine 3',5'-monophosphate (cyclic AMP) levels in rat cortex, hippocampus, striatum and cerebellum. The largest effect observed was a 60% increase in cortical cyclic AMP levels in rats administered aluminum sulfate. The effects of orally administered aluminum on guanosine 3',5'-monophosphate (cyclic GMP) levels were less widespread. Dietary aluminum citrate only elevated cyclic GMP levels in the hippocampus, while aluminum sulfate caused significant increases in the cerebellum, hippocampus and striatum. Aluminum citrate administered i.c.v. (1 mumol, 2 weeks postadministration) elevated cyclic AMP levels in the cortex, but had no effect on cyclic GMP levels. Aluminum administered either orally or i.c.v. had no effect on in vivo acetylcholine levels. However, dietary aluminum citrate significantly reduced choline levels in the cortex, hippocampus and striatum. Aluminum administered i.c.v. had no effect on choline acetyltransferase activity or on high-affinity choline transport. These results indicate that: the metabolism of cyclic AMP and of cyclic GMP are more sensitive to aluminum than are presynaptic cholinergic processes; the metabolism of cyclic AMP is more sensitive to the effects of aluminum than is the metabolism of cyclic GMP; and cortical cAMP metabolism is the most sensitive to the presence of aluminum. Possible consequences of elevated levels of cyclic nucleotides induced by aluminum in the brain are proposed.

Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells.

In Alzheimer's Disease brain, the microtubule-associated protein tau is hyperphosphorylated at specific epitopes and abnormally aggregates into filamentous structures. In addition, there is significant neurodegeneration in Alzheimer's disease brain, and there is data to suggest that apoptotic-like processes may contribute to the neurodegeneration. It has been demonstrated that in PC12 cells undergoing apoptosis due trophic factor removal, tau is hyperphosphorylated prior to chromatin condensation. To establish that increased tau phosphorylation is a generalized outcome of the apoptotic process, and to examine the involvement of the protein kinase in these events, apoptosis was induced in retinoic-acid differentiated human SH-SY5Y neuroblastoma cells using the topoisomerase-1 inhibitor camptothecin. Treatment of the differentiated SH-SY5Y cells with camptothecin resulted in a time and concentration dependent activation of caspase-3 with a concomitant increase in the presence of apoptotic nuclei. Immunoblotting revealed that camptothecin treatment resulted in a significant increase in tau phosphorylation. Addition of a cyclin-dependent kinase inhibitor reduced camptothecin-induced cell death in the differentiated SH-SY5Y cells and decreased the effects of camptothecin on tau phosphorylation. In contrast, a general caspase inhibitor decreased camptothecin-induced cell death, but did not significantly decrease the increases in tau phosphorylation. These results suggest that increased tau phosphorylation is likely a generalized outcome of apoptotic processes in neuron-related cells, and that cyclin-dependent kinases probably play a role in this process.

Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide.

One of the major pathological characteristics of Alzheimer's disease is the increased number of amyloid-containing senile plaques within the brain. The dense cores of these plaques are composed primarily of highly insoluble aggregates of a 39-43-residue peptide referred to as the beta-amyloid peptide (beta A). The mechanisms by which these insoluble extracellular deposits of beta A are formed remain unknown. In this study, the cross-linking of beta A by the calcium-dependent enzyme, transglutaminase was examined. Transglutaminases are a family of enzymes which are found in brain, and catalyse the cross-linking of specific proteins into insoluble polymers. Synthetic beta A (1-40) was readily cross-linked by transglutaminase, forming multimers in a time-dependent fashion. Furthermore, a second peptide with a substitution similar to that in the Dutch-type hereditary amyloidosis mutation (Glu22 to Gln) was also found to be a substrate for transglutaminase. Since transglutaminase covalently cross-links proteins through glutamine residues, it is suggested that transglutaminase contributes to amyloid deposition in Dutch-type hereditary amyloidosis, and possibly Alzheimer's disease.